Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Concetta Ferracane
Observed names:
C Ferracane,
C. Ferracane
Institution:
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
Observed institutions:
University of Catania,
Ospedale Cannizzaro,
Azienda Ospedaliera Universitaria Policlinico "G. Martino",
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo,
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
ORCID:
0009-0002-2686-191X
Observed ORCID:
0009-0002-2686-191X
OpenAlex ID:
A5075167160
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases
2018
·
Fabio Salvatore Macaluso
, Rosalba Orlando
, et al.
·
Digestive and Liver Disease
·
46
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn’s Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease
2018
·
Fabio Salvatore Macaluso
, Walter Fries
, et al.
·
Journal of Crohn s and Colitis
·
38
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2020
·
the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
, Serena Porcari
, et al.
·
Drugs & Aging
·
29
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
2021
·
Fabio Salvatore Macaluso
, Maria Cappello
, et al.
·
Journal of Gastroenterology and Hepatology
·
26
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis
2020
·
Fabio Salvatore Macaluso
, Marco Ventimiglia
, et al.
·
Digestive and Liver Disease
·
26
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19
2022
·
Fabio Salvatore Macaluso
, Alessandra Giuliano
, et al.
·
Inflammatory Bowel Diseases
·
22
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease
2023
·
Fabio Salvatore Macaluso
, Mauro Grova
, et al.
·
Journal of Gastroenterology and Hepatology
·
21
PDF
Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
2021
·
Anna Viola
, Marco Muscianisi
, et al.
·
JGH Open
·
21
PDF
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis
2018
·
Sara Renna
, Filippo Mocciaro
, et al.
·
Digestive and Liver Disease
·
21
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease
2021
·
Fabio Salvatore Macaluso
, Maria Cappello
, et al.
·
Digestive and Liver Disease
·
16
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2020
·
Fabio Salvatore Macaluso
, Walter Fries
, et al.
·
Expert Opinion on Biological Therapy
·
15
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis
2019
·
Fabrizio Bossa
, Giuseppe Biscaglia
, et al.
·
Digestive Diseases and Sciences
·
15
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study
2023
·
Fabio Salvatore Macaluso
, Elvira D'Antonio
, et al.
·
Digestive and Liver Disease
·
12
PDF
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study
2026
·
Franco Scaldaferri
, Federica Di Vincenzo
, et al.
·
The American Journal of Gastroenterology
·
11
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study
2025
·
Fabio Salvatore Macaluso
, Walter Fries
, et al.
·
Journal of Crohn s and Colitis
·
6
The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases
2024
·
Fabio Salvatore Macaluso
, Sara Renna
, et al.
·
Inflammatory Bowel Diseases
·
6
PDF
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class
2025
·
Tommaso Innocenti
, Jurij Hanžel
, et al.
·
Journal of Crohn s and Colitis
·
4
Real‐World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease—A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases ( IG ‐ IBD )
2026
·
Brigida Barberio
, Ferdinando D'Amico
, et al.
·
Alimentary Pharmacology & Therapeutics
·
2
PDF
T.10.1 Safety and Effectiveness of Tofacitinib in Ulcerative Colitis: Real-world Data From Tofa-uc, a Sn-ibd Study
2023
·
F.S. Macaluso
, E. D'Antonio
, et al.
·
Digestive and Liver Disease
·
2
P0598 MIRACLE-UC: Mirikizumab Investigation of Real-world Assessment of Clinical and Long-term Effectiveness and Adverse Events in Patients with Ulcerative Colitis - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
2026
·
B Barberio
, A Todeschini
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study
2025
·
Fabio Salvatore Macaluso
, Walter Fries
, et al.
·
Digestive and Liver Disease
·
1
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis-Associated Spondyloarthropathy: a multicenter prospective study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD)
2025
·
Fabio Salvatore Macaluso
, Mauro Grova
, et al.
·
Therapeutic Advances in Gastroenterology
·
1
P0854 The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2025
·
F S Macaluso
, S Renna
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
Pc.01.3 Severe Activity of Inflammatory Bowel Disease Is a Risk Factor for Severe Covid-19: Data From the Sicilian Network for Inflammatory Bowel Disease (sn-ibd)
2021
·
F.S. Macaluso
, A. Giuliano
, et al.
·
Digestive and Liver Disease
·
1
PDF
Af.51 Vedolizumab May Be an Effective Option for the Management of Postoperative Recurrence of Crohn’s Disease
2021
·
F.S. Macaluso
, M. Cappello
, et al.
·
Digestive and Liver Disease
·
1
PDF
Show more works
View as search
Works count:
56
Citation count:
348
H-index:
12
I10-index:
14
Year
Topic
Type